Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly And China's Hisun Complete Technology Transfer For Antibiotic Capreomycin For TB

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Eli Lilly and Chinese active pharmaceutical ingredient provider Hisun recently announced the completion of a technology transfer under which Lilly transferred technology to Hisun to produce finished products and API of its tuberculosis drug capreomycin

You may also be interested in...



China’s Hisun Gets Capreomycin WHO Prequalification

Hisun’s pre-qualification approval for capreomycin to treat second-line active tuberculosis cases may help bring costs down for a drug increasingly in demand as multi-drug resistant patients multiply worldwide.

Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report

HONG KONG - Growing economies, improved diets and access to healthcare are having a positive effect on health across Asia, but the incidence of infectious diseases remains stubbornly high and the impact is compounded by rises in non-communicable lifestyle diseases. The latest set of statistical data from the World Health Organization suggests more and more countries are forced to tackle both simultaneously, and global and local pharma companies are racing to fill unmet needs

Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report

HONG KONG - Growing economies, improved diets and access to healthcare are having a positive effect on health across Asia, but the incidence of infectious diseases remains stubbornly high and the impact is compounded by rises in non-communicable lifestyle diseases. The latest set of statistical data from the World Health Organization suggests more and more countries are forced to tackle both simultaneously, and global and local pharma companies are racing to fill unmet needs

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel